Another Eli Lilly oncology drug is in trouble, as Japan issues Verzenio safety warning
Eli Lilly is in trouble, again. This year, a late-stage failure prompted the withdrawal of its cancer drug Lartruvo; its erectile dysfunction treatment Cialis is being eaten up by generic competition; and in the first quarter, the US drugmaker relegated two mid-stage drugs to the scrap heap. Now, reports have emerged that Japan has flagged safety concerns associated with its breast cancer treatment, Verzenio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.